Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins
This article was originally published in The Pink Sheet Daily
Executive Summary
Small molecule projects in development will be out-licensed, including the Phase I glucokinase activator NN9101.